Additionally, the activation of MEK/ERK pathway also contributes to MM cell resistance to IMiDs.52 Our aforementioned results indicated that PM significantly inhibited “RAF-MEK-ERK-AKT” signaling pathway.53 Importantly, this synergistic therapeutic effect was also confirmed in the r/r MM patients in phase Ib/IIa, although only 2 patients were included so far (Supplementary Fig. 7). The gene discussed is AKT1; the disease is Miyoshi myopathy.